-AZA is safe in pregnancy but can cause risk of ICP. -Monitor pts on AZA closely for ICP symptoms. #ACR26 @RheumNow https://t.co/v9mNKVNKcm

Emergence of systemic autoimmune rheumatic diseases can occur in menopause and difficult to differentiate from "MS syndrome of Menopause" HRT: Safe in Non-SLE autoimmune disease/SLE with negative APL+ use with caution/Not recommended in APL+/APS #ACR26 @RheumNow https://t.co/6al61n1ck3

-Biologic DMARDs are generally safe for pregnancy: ETA and CZP safer compared to others. -B cell depletion can be used in pregnancy but caution about neonatal cytopenias for first 6m if dosed in 2nd half og pregnancy. -Counsel on vaccination for biologic exposed babies. #ACR26 https://t.co/byQgPpAveT

After stopping TCZ in GCA (~2 yrs exposure), over HALF of pts still flared w/in 72 weeks, even among pts w/imaging remission Most flares 3-6 mos post stopping Good evidence for continuing longer; I continue many pts on TCAZ up to 5 years post dx @RheumNow #ACR26 Ab#0186 https://t.co/yq0rXv1l3S

Nice RWE study of UPA in GCA Refractory cohort w/multiple prior biologics; 22/34 evaluable pts had clinical remission at 6 months; 7/63 stopped for severe adverse events. Useful real-world signal, overall corroborates SELECT-GCA @RheumNow #ACR26 Ab#0184 https://t.co/hGRFAoV6B4

Exercise is essential for pts w/myositis Improved fatigue and reduced disability among pts with myositis who engaged with structured exercise programs No comparator & small, but important message to pts who are often nervous about working out @RheumNow #ACR26 Ab#0652 https://t.co/c4tejsWQYk

Beyond Chondrocalcinosis - What’s New in CPPD Disease An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and https://t.co/YrFjGJZDph

Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/Olynr7VfhE

Japanese retrospective cohort systemic sclerosis study shows adjunctive tofacitinib improved ower esophageal sphincter pressures (LESP). 50 SSc pts w/ esophageal Sxs Rx w/ Tofa or PBO x 24 wks. Tofa assoc w/ signif LESP increases & lower mRSS & IL-6 levels https://t.co/NNREBddiOi https://t.co/acVOfoorRP

Women's Health and Reproductive Issues: APLAR 2026 https://t.co/E3IjKP91qL https://t.co/imOGOjce83

Autologous HCT in Severe Systemic Sclerosis An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation, adding important evidence on sustained positive clinical outcomes and long-term safety in patients treated for early https://t.co/2YhuAwMsXe

Three Tips to Stay on Muscarinic Agonists in Sjögren's Disease Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026. https://t.co/WrG8UF8Sne https://t.co/QMmZfUYWLq

Big meeting. Plenty to talk about. Join RheumNow’s daily ACR 2026 recaps for standout data, thoughtful debate and clinical takeaways. Sunday, Nov. 8–Wednesday, Nov. 11 6 PM ET / 5 PM CT / 3 PM PT Watch LIVE on X, YouTube, Facebook or LinkedIn. https://t.co/SX6sSX9Tbe

Medscape overview of Fibromyalgia Therapies. Only four FDA approved FM drugs in the USA - pregabalin (2007), duloxetine (2008), milnacipran (2009) & sublingual cyclobenzaprine (2025) but none approved by the EMA in Europe. https://t.co/QHFSmcozT0 https://t.co/oiVjf4GZGX

APLAR 2026: Who can reduce DMARDs in RA? https://t.co/npUC1hjlYT https://t.co/ExnNEe9gZQ